A deal has been struck by the NHS to secure a non-branded ‘generic’ version of the drug, sapropterin dihydrochloride, for patients with the inherited condition, which means patients cannot eat protein.

Clinical trials suggest that around four in 10 people may benefit from sapropterin, improving their quality of life significantly and reducing restrictions on the food they can eat.

Read more – NHSE & I (17/12/21)